The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy
Abdom Radiol (NY). 2021 Aug;46(8):3686-3697. doi: 10.1007/s00261-021-03192-8.Epub 2021 Jun 30.
Sandeep Arora12, Roberta Catania3, Amir Borhani3, Natally Horvat4, Kathryn Fowler5, Carla Harmath6
Author information
1Yale New Haven Hospital, New Haven, CT, USA.
2Vanderbilt University, Nashville, TN, USA.
3Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
4Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5University of California San Diego, La Jolla, CA, USA.
6University of Chicago Pritzker School of Medicine, 5841 S. Maryland Avenue, MC 2026, Chicago, IL, 60637, USA. charmath@radiology.bsd.uchicago.edu.
Abstract
Liver cancer is the fastest-growing cause of cancer deaths in the United States and is a complex disease. The response of hepatocellular carcinoma (HCC) to treatment can be variable. Predicting response to determine the most effective therapy is an active area of research. Our understanding of underlying factors which drive response to therapy is continually increasing. As more therapies for the treatment of this disease evolve, it is crucial to identify and match the ideal therapy for a particular tumor and patient. The potential predicative imaging features of tumor behavior, while of research interest, have not been validated for clinical use and do not currently inform treatment planning. If further validated though, prognostic features may be used in the future to personalize treatment plans according to individual patients and tumors. Unexpected post-treatment responses such as potential tumor biology changes and abscopal effect which are important to be aware of. This review is intended for radiologists who routinely interpret post treatment HCC imaging and is designed to increase their cognizance about how HCC tumor biology drives response to therapy and explore rare responses to therapy.